NSAUA 2018: Retrograde Intra-Renal Surgery for Renal Calculi: What is the Limit?

Toronto, Ontario (UroToday.com) Dr. Denstedt gave the last discussion on stone disease in the Northeastern Section Annual meeting in Toronto. This talk focused on the limits of retrograde intra-renal surgery (RIRS) for renal stones.

NSAUA 2018: The Importance of Endoscopic Observations of the Renal Papillae

Toronto, Ontario (UroToday.com) James E. Lingeman, MD gave a talk on new concepts in renal stone formation. Endoscopic observation of renal papillae is most important. This allows the surgeon to understand stone pathogenesis pathways, distinguish nephrolithiasis from nephrocalcinosis, provide the surgeon with the most sensitive method to identify stones, and enables urologists to have a grading system of papillary injury.

NSAUA 2018: Non-Metastatic Castration Resistant Prostate Cancer

Toronto, Ontario (UroToday.com) Oliver Sartor argues the state of non-metastatic castration resistant prostate cancer (nmCRPC) does not even really exist, and there are a number of reasons for that. CT and bone scan can detect tumors with a volume of at least 1 cc, but 1 cc tumors may contain as many as 1,000,000,000 cells! That means that with these conventional imaging we are most likely missing many metastatic lesions that are already present. Newer molecular imaging is 10-50 times more sensitive than conventional bone and CT scans. These include the new PET PSMA, PET Fluciclovine, and PET Choline. Clinical trial inclusion and endpoints can be dramatically altered by newer imaging techniques. In the present and the near future, molecular imaging will redefine prostate cancer patients with “localized”, “oligometastatic” and  “nmCRPC” disease.

NSAUA 2018: The Curability of Invasive Bladder Cancer

Toronto, Ontario (UroToday.com) S. Bruce Malkowicz, MD gave a presentation on the curability of muscle-invasive bladder cancer (MIBC). He began his talk stating the barriers to curing MIBC. These include:

NSAUA 2018: Is Radical Nephrectomy Even an Option in the Face of Metastatic Renal Cell Carcinoma?

Toronto, Ontario (UroToday.com) Eric Kauffman, MD gave a talk on the contemporary role of cytoreductive nephrectomy in metastatic renal cell carcinoma (RCC). He began his talk, asking the controversial question of whether in the contemporary era, is cytoreductive nephrectomy dead?

NSAUA 2018: The Optimal Management of Non-Muscle Invasive Bladder Cancer

Toronto, Ontario (UroToday.com) Non-muscle invasive bladder cancer (NMIBC) is the most expensive cancer for the health care system. It entails repeat surgeries under anesthesia, long-term monitoring with cystoscopies, multiple intravesical therapies and more.  NMIBC is also cancer with the most rapid increase in incidence with the aging population. NMIBC can be categorized as either low, intermediate or high-risk disease, with a recurrence rate of  30%, 50-60%, and 70-80% respectively, and progression rates of <1%, <5%, and 10-30%, respectively.

NSAUA 2018: Evaluation and Management of Women with Recurrent Stress Urinary Incontinence

Toronto, Ontario (UroToday.com) The topic of recurrent stress urinary incontinence after initial surgical therapy in women was discussed in this talk by E. Ann Gormley, MD. In recurrent stress urinary incontinence (SUI) the severity of the incontinence occurring following a failed surgery can either be the same or might even be worse. This entity of recurrent SUI after initial failed surgical therapy can be divided into several entities:
Page 1 of 2

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.